esp | eng
HISTORY


HISTORY

Half a Century of History:

2012 Cetraxal plus is launched in Mexico as Infalin
2011 Cetraxal plus is launched in Italy as Cexidal
2010 Approval of Cetraxal Otic Solution in Europe through a descentralized procedure
2009 FDA approves Cetraxal Otico Solution, which is then marketed in the USA in collaboration with WraSer Pharmaceuticals
2008 Malacur is launched in Africa
2007 Blow-Fill-Seal technology is introduced at our production facility
2006 Approval letter for Cetraxal in USA and IND for Tarafenacin
2005 Launch of Levogastrol and Eberconazole (a new chemical entity with worldwide patent)
2002 Cetraxal Plus Ear Drops are launched (unique combination)
2001 Zayasel Solution launch
2000 Inauguration of the new R&D Centre
1997 Monolitum is launched
1995 Cetraxal Ear drops (a world first) are launched
1989 Cetraxal is launched
1987 Ulcetrax is launched with the “SALVAT original process patent”
1986 The OTC Division is created, and Cristalmina is launched
1984 SALVAT moves to its current headquarters
1982 SALVAT’s International Division is created
1973 INSALQUISA is established
1972 Vinciseptil Otico is launched
1959 SALVACOLINA is launched
1955 SALVAT Laboratory is established

 



Laboratorios SALVAT S.A.
C\ Gall, 30-36 08950 - Esplugues de Llobregat - Barcelona España Tel. +34 933 946 400 Fax. +34 934 732 292 salvat@svt.com
1200 Brickell Avenue, Suite 1950, Miami, FL 33131 (US) Tel. +1 786-528-5273 salvatusa@svt.com